Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 7Unknown 3Recruiting 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Head & Neck 1Breast 1

Conditions

Polycystic Ovary Syndrome 7Neoplasms 3Melanoma 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Ovarian Neoplasms 2Obesity 2Infertility 2Glioblastoma 2Endometrial Neoplasms 2Breast Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Cervical Neoplasms 1TP53 Y220C Mutation 1Sarcoma, Ewing 1Sarcoma 1Prostate Cancer Recurrent 1Progression-Free Survival 1Preleukemia 1Posterior Fossa Ependymal Tumor 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Metabolic Diseases 1Medulloblastoma 1Leukoplakia, Oral 1Leukemia, Myeloid, Acute 1Insulin Resistance 1Hyperandrogenism 1

Interventions

pembrolizumab 25Paclitaxel 20Carboplatin 17Bevacizumab 12Specimen Handling 10Letrozole 10abemaciclib 7dostarlimab 6Taxes 6Blood Specimen Collection 6Medroxyprogesterone Acetate 5Magnetic Resonance Spectroscopy 5Fulvestrant 5Drug Therapy 5Doxorubicin 5Cisplatin 5Biopsy 5olaparib 4lenvatinib 4atezolizumab 4Radiotherapy 4Progestins 4Observation 4Nivolumab 4Megestrol Acetate 4Immunoglobulin G 4Gemcitabine 4trastuzumab deruxtecan 3palbociclib 3X-Rays 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Endometrial Neoplasms × Metformin × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT03675893 2025-06-15

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

Dana-Farber Cancer Institute

Phase 2 Recruiting
180 enrolled
Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡